DA
BIO icon

Denali Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Denali Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-900
Closed -$671K – 382
2021
Q3 		$671K Buy
900
+100
+13% +$74.9K 0.28% 94
2021
Q2 		$515K Sell
800
-2,200
-73% -$1.34M 0.2% 93
2021
Q1 		$1.71M Buy
+3,000
New +$1.78M 0.53% 67
2014
Q2 		– Sell
-23,200
Closed -$2.97M – 264
2014
Q1 		$2.97M Buy
+23,200
New +$2.97M 0.86% 47

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Denali Advisors's BIO Position: Q4 2021 in Review

Denali Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2021, closing a stake of 900 shares — an estimated $671K sold.

Denali Advisors first reported a position in BIO in Q1 2014 and held it in 4 quarters. The position peaked at $2.97M in Q1 2014. 533 funds tracked by Wall St. Rank hold BIO as of Q4 2021.

  • Denali Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q4 2021 after selling out during the quarter.
  • Denali Advisors sold 900 Bio-Rad Laboratories Class A shares in Q4 2021, an estimated $671K.
  • Denali Advisors first reported a position in Bio-Rad Laboratories Class A in Q1 2014 and held it in 4 quarters.
  • Denali Advisors's Bio-Rad Laboratories Class A position peaked at $2.97M in Q1 2014.
  • 533 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2021.

Based on Denali Advisors's 13F filing for Q4 2021, filed 21 Jan 2022.